High-Risk Melanoma

New Vaccine Combo May Cure Deadly Melanoma

Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma

SG Tylor

Source – Merck Moderna and Merck  announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...